Breaking News
Subscribe Now 0
🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screener
Try Stock Screener
Close

Pictet-biotech R Eur (0P00007WAN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
756.070 +2.000    +0.27%
07:00:00 - Closed. Currency in EUR
Type:  Fund
Market:  Luxembourg
Issuer:  Pictet Asset Management (Europe) SA
ISIN:  LU0255977539 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 1.51B
Pictet Biotech R EUR 756.070 +2.000 +0.27%

Pictet-biotech R Eur Overview

 
On this page you'll find an in-depth profile of Pictet-biotech R Eur. Learn about the key management, total assets, investment strategy and contact information of 0P00007WAN among other information.
Category

Sector Equity Biotechnology

Total Assets

1.51B

Expenses

2.70%

Inception Date

Jun 14, 2006

Investment Strategy

To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs.

Contact Information

Address Calle Hermosilla 11
Madrid,Madrid 28001
Spain
Phone +34 91 781 6520
Fax Milan

Top Executives

Name Title Since Until
Eugénio Martin-Fougeroux - 2023 Now
Marco Minonne Vice President 2020 Now
Biography Marco Minonne, CFA, Senior Vice President, rejoined the firm in 2013. Marco is part of the Growth Equity Group which is responsible for Neuberger Berman’s Mid Cap Growth and Small Cap Growth strategies. He is an Associate Portfolio Manager on Small Cap Growth and a Research Analyst covering the health care sector on Mid Cap Growth. Prior to rejoining Neuberger Berman, Marco was a senior therapeutic analyst with Columbia Management. He has previously held research analyst positions at Citadel Investment Group, Neuberger Berman and Northern Trust Bank. Marco has extensive buy-side experience in health care and has been involved in both long-only and long-short strategies. Marco earned a Bachelor of Arts in Finance and Economics from the University of Iowa and has been awarded the Chartered Financial Analyst designation.
Tazio Storni - 2016 Now
Lydia Haueter - 2016 Now
Grégoire Biollaz - 2016 2017
Nathalie Flury - 2016 2017
Michael Sjöström - 1995 2016
Carmen Tang - 2008 2012
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P00007WAN Comments

Write your thoughts about Pictet-biotech R Eur
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email